The nation of Zimbabwe has rejected a substantial US healthcare agreement valued at $367m (£272m) over five years over Washington's demand for sensitive information.
The decision came to light after a internal memorandum dated December was disclosed, revealing that President Emmerson Mnangagwa felt the deal was "unbalanced".
A government spokesman later stated that the United States was demanding access to biological samples for research and commercial purposes while was unwilling to share the benefits from future vaccines.
"We will now turn to the challenging and unfortunate task of ending our health aid in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy said the US had donated more than $1.9bn for health programmes to Zimbabwe over the last two decades.
A medical body in Zimbabwe has called for continued negotiations to secure a agreement acceptable to both sides so the nation's vital HIV programme can be sustained.
Wider Implications
This development follows a comparable situation in Kenya, where a high court blocked a related deal with the US after concerns were raised about the security of Kenyans' medical information.
Since returning to the presidency last year, US President Donald Trump has slashed overseas assistance and closed the key foreign aid agency.
USAID had administered aid for the US government, but Trump claimed its spending was "inefficient" and his administration was seeking direct bilateral agreements to enhance openness and responsibility.
Based on statements, Sixteen African countries have to date signed these new health pacts, representing more than $18.3bn in new funding.
Specifics of the Declined Deal
This assistance for Zimbabwe was intended to gone towards "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"It is our view this collaboration could have provided significant benefits for Zimbabwean communities, particularly the 1.2 million currently receiving antiretroviral therapy via American-funded programmes," Tremont commented.
However, government spokesperson Nick Mangwana argued the proposed deal was "asymmetrical".
"Zimbabwe was being asked to provide its biological resources and data for a long time, without any corresponding guarantee of benefiting from any scientific breakthroughs – such as new medicines or tests – that could be developed from that shared data," Mangwana explained.
"Put simply, our country would provide the raw materials for scientific discovery with no assurance that the final treatments would be available to our citizens if a future disease outbreak emerge."
National Interest and Global Health
Mangwana further pointed out that the American exit from the global health body and its push of bilateral health agreements were disrupting frameworks already established via the international health agency.
Mangwana gave as an example its Pathogen Access and Benefit Sharing scheme designed to deal with future global health emergencies.
"This framework is intended to ensure that when a nation contributes its data, the resulting advantages – including medicines and cures – are shared equitably, not monopolised solely by those with the resources to develop them."
The government's concerns over the US deal "are not meant as opposition to America," he added.
"We are open to ongoing dialogue with our American counterparts on how future collaboration might be designed in a manner that respects the independence and dignity of each country."
Health Experts Response
Medical experts said it understood the official position, but urged that negotiations need to persist since a large portion of the nation's HIV programmes depended on external financing.
"In cases where technical issues arise, such as those involving information security or implementation frameworks, these can often be addressed through detailed discussion and negotiated safeguards," it commented.
The halted deal underscores the ongoing debate between receiving vital foreign assistance and protecting a country's data in an ever more data-driven world.